Clinical Trials

200 enrolled 27 charts

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07460752 2026-03-10

Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients

98 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT06348134 2026-02-17

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

74 enrolled

Breast Neoplasms

NCT07158021 2026-02-13

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial

75 enrolled

Breast Neoplasms

NCT02624973 2026-02-12

PETREMAC

200 enrolled

Breast Neoplasms

NCT03056755 2026-01-13

BYLieve

383 enrolled 16 charts

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT01723774 2025-12-09

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

84 enrolled 17 charts

Breast Neoplasms

NCT03671330 2025-10-31

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

327 enrolled

Breast Neoplasms

NCT05607004 2025-10-30

EVANGELINE

87 enrolled

Breast Neoplasms

NCT03822468 2025-10-16

AMALEE

376 enrolled 17 charts

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07179939 2025-09-18

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

288 enrolled

HER2-positive Breast Cancer

NCT02476786 2025-07-28

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

50 enrolled

Breast Neoplasms

NCT06953882 2025-07-14

SELECT

140 enrolled

HER2 Negative Breast Cancer

NCT03839823 2024-10-09

RIGHT Choice

222 enrolled 17 charts

Breast Neoplasms

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

620 enrolled

Breast Neoplasms

NCT05163106 2024-08-02

NEOLETRIB

85 enrolled

Breast Neoplasms

NCT04862143 2024-06-20

TELEPIK

2 enrolled 10 charts

Advanced Breast Cancer

NCT05720260 2024-06-10

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

42 enrolled

Breast Neoplasms

NCT03272477 2024-04-17

TP-II

257 enrolled

Breast Neoplasms

NCT03007979 2024-03-20

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

55 enrolled 15 charts

Breast Neoplasms

NCT01989780 2022-08-04

BOOSTER

160 enrolled

Breast Neoplasms

NCT03628066 2022-04-20

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

24 enrolled

Breast Neoplasms

NCT02907918 2021-09-29

PALTAN

26 enrolled 8 charts

Breast Neoplasms

NCT02603679 2021-08-03

PREDIX LumB

181 enrolled

Breast Neoplasms

NCT02592083 2020-07-07

PREDIX LumA

10 enrolled

Breast Neoplasms

NCT00186121 2019-10-07

Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women

35 enrolled 11 charts

Breast Neoplasms

NCT01776008 2018-05-08

Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer

16 enrolled 5 charts

Breast Neoplasms

NCT03444025 2018-02-23

NeoGONT

180 enrolled

Triple Negative Breast Neoplasms

NCT01266213 2017-05-01

FLAG

147 enrolled

Breast Neoplasms

NCT00010010 2016-03-11

Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer

Breast Neoplasms

NCT01368263 2015-04-03

Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer

8 enrolled 5 charts

Breast Neoplasms

NCT02072512 2014-02-26

PROOF

180 enrolled

Breast Neoplasms

NCT01240941 2013-08-20

Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT01013506 2013-05-23

Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT00498901 2013-05-09

Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer

1 enrolled

Breast Neoplasms

NCT00217659 2013-01-03

S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms, Breast Neoplasms, Male

NCT01205685 2012-09-11

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

11 enrolled 9 charts

Hormone-sensitive Metastatic Breast Cancer

NCT00532272 2011-06-27

Goserelin/Letrozole in Premenopausal Patients vs Letrozole Alone in Postmenopausal Patients With MBC

78 enrolled

Breast Neoplasms

NCT00322348 2011-01-24

Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women

98 enrolled 13 charts

Breast Neoplasms, Neoplasms

NCT00235937 2011-01-21

Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex

45 enrolled

Breast Neoplasms

NCT00398489 2010-11-09

Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery

94 enrolled

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00303524 2009-12-23

Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients

170 enrolled